These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
754 related articles for article (PubMed ID: 33181091)
1. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Gong Y; Ji P; Yang YS; Xie S; Yu TJ; Xiao Y; Jin ML; Ma D; Guo LW; Pei YC; Chai WJ; Li DQ; Bai F; Bertucci F; Hu X; Jiang YZ; Shao ZM Cell Metab; 2021 Jan; 33(1):51-64.e9. PubMed ID: 33181091 [TBL] [Abstract][Full Text] [Related]
2. Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction. Coleman MF; O'Flanagan CH; Pfeil AJ; Chen X; Pearce JB; Sumner S; Krupenko SA; Hursting SD Nutrients; 2021 May; 13(5):. PubMed ID: 34068120 [TBL] [Abstract][Full Text] [Related]
3. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563 [TBL] [Abstract][Full Text] [Related]
4. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Yang F; Xiao Y; Ding JH; Jin X; Ma D; Li DQ; Shi JX; Huang W; Wang YP; Jiang YZ; Shao ZM Cell Metab; 2023 Jan; 35(1):84-100.e8. PubMed ID: 36257316 [TBL] [Abstract][Full Text] [Related]
5. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455 [TBL] [Abstract][Full Text] [Related]
6. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer. Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400 [TBL] [Abstract][Full Text] [Related]
7. Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression. Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Deladriere C; Palomino-Schätzlein M; Lamas-Domingo R; Forteza J; Pineda-Lucena A; Vicent MJ Int J Cancer; 2019 Oct; 145(8):2267-2281. PubMed ID: 30860605 [TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360 [TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of Triple-Negative Breast Cancer. Derakhshan F; Reis-Filho JS Annu Rev Pathol; 2022 Jan; 17():181-204. PubMed ID: 35073169 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939 [TBL] [Abstract][Full Text] [Related]
11. Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. Liao C; Glodowski CR; Fan C; Liu J; Mott KR; Kaushik A; Vu H; Locasale JW; McBrayer SK; DeBerardinis RJ; Perou CM; Zhang Q Cancer Res; 2022 Feb; 82(4):665-680. PubMed ID: 34911787 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes. Kim NI; Park MH; Cho N; Lee JS Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):246-256. PubMed ID: 35384874 [TBL] [Abstract][Full Text] [Related]
13. Altered gene expression in glycolysis-cholesterol synthesis axis correlates with outcome of triple-negative breast cancer. Zhong PC; Shu R; Wu HW; Liu ZW; Shen XL; Hu YJ Exp Biol Med (Maywood); 2021 Mar; 246(5):560-571. PubMed ID: 33243007 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer. Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW Cells; 2021 Jul; 10(8):. PubMed ID: 34440660 [TBL] [Abstract][Full Text] [Related]
15. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Michaels E; Chen N; Nanda R Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. Asleh K; Riaz N; Nielsen TO J Exp Clin Cancer Res; 2022 Sep; 41(1):265. PubMed ID: 36050786 [TBL] [Abstract][Full Text] [Related]
17. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. Zhou Y; Che Y; Fu Z; Zhang H; Wu H Front Public Health; 2022; 10():902378. PubMed ID: 35875026 [TBL] [Abstract][Full Text] [Related]
18. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198 [TBL] [Abstract][Full Text] [Related]
20. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer. Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]